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Brief Definit ive Report
Survival of peripheral mature B cells depends on 
their stimulation via the receptor for the cytokine 
BAFF (B cell activating factor; Mackay et al., 
2010). BAFF-receptor (BAFF-R; TNFRSF13) ex-
pression is induced on newly formed immature 
B cells in the BM and increases in the spleen as 
transitional B cells mature to become follicular or 
marginal zone B cells (Mackay et al., 2010). In 
BAFF or BAFF-R–deficient mice, B cell devel-
opment is blocked at the transitional T1–T2 de-
velopmental step in the spleen, and numbers of 
mature follicular and marginal zone B cells are 
substantially reduced (Batten et al., 2000; Yan et al., 
2001). In contrast, B1 B cells do not require BAFF 
for their survival. Transgenic overproduction of 
BAFF in mice induces the expansion of the B cell 
compartment and the development of an auto-
immune disease resembling systemic lupus ery-
thematosus (SLE; Mackay et al., 1999). The levels 
of BAFF in vivo therefore control the size of the 
mature B cell pool.
Stimulation of BAFF-R activates several 
intracellular signaling pathways that promote cell 
survival. These include those leading to the ac-
tivation of NF-B transcription factors, which 
induce the expression of pro-survival proteins, 
such as the Bcl-2 family proteins Bcl-xl and A1 
(Rickert et al., 2011). BAFF strongly activates 
the alternative NF-B pathway (Razani et al., 
2011), which stimulates the partial proteolysis of 
NF-B2 p100 to p52 via IB kinase 1 (IKK1), 
resulting in nuclear translocation of p52/RelB 
heterodimers (Beinke and Ley, 2004). However, 
conditional deletion of Ikk1 in the B cell lin-
eage has recently demonstrated that IKK1 is 
dispensable for BAFF-induced mature B cell 
survival and is also not required for the develop-
ment of a substantial fraction of mature B cells 
(Jellusova et al., 2013). BAFF also weakly activates 
the canonical IKK2-regulated NF-B pathway 
that stimulates the proteolysis of IB, promot-
ing the nuclear translocation of NF-B1 p50/
RelA heterodimers. Mature B cell numbers are 
substantially reduced by B cell–specific dele-
tion of IKK2 (Pasparakis et al., 2002). Further-
more, expression of constitutively active IKK2 
substitutes for BAFF-R deficiency for generation 
of peripheral mature B cells (Sasaki et al., 2006). 
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B cell activating factor (BAFF) stimulation of the BAFF receptor (BAFF-R) is essential for 
the homeostatic survival of mature B cells. Earlier in vitro experiments with inhibitors that 
block MEK 1 and 2 suggested that activation of ERK 1 and 2 MAP kinases is required for 
BAFF-R to promote B cell survival. However, these inhibitors are now known to also inhibit 
MEK5, which activates the related MAP kinase ERK5. In the present study, we demon-
strated that BAFF-induced B cell survival was actually independent of ERK1/2 activation 
but required ERK5 activation. Consistent with this, we showed that conditional deletion of 
ERK5 in B cells led to a pronounced global reduction in mature B2 B cell numbers, which 
correlated with impaired survival of ERK5-deficient B cells after BAFF stimulation. ERK5 
was required for optimal BAFF up-regulation of Mcl1 and Bcl2a1, which are prosurvival 
members of the Bcl-2 family. However, ERK5 deficiency did not alter BAFF activation of 
the PI3-kinase–Akt or NF-B signaling pathways, which are also important for BAFF to 
promote mature B cell survival. Our study reveals a critical role for the MEK5-ERK5 MAP 
kinase signaling pathway in BAFF-induced mature B cell survival and homeostatic mainte-
nance of B2 cell numbers.
© 2015 Jacque et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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We reinvestigated the role of ERK1/2 activation in BAFF-
induced B cell survival using a second-generation MEK1/2 
inhibitor, PD184352, which inhibits MEK1/2 and MEK5 
with different potencies (Bain et al., 2007). 2 µM PD184352, 
a concentration that inhibits MEK1/2 but not MEK5, did 
not affect BAFF-induced survival of murine splenic follicular 
mature (FM) B cells (Fig. 1 A and Fig. S1), although BAFF-
induced ERK1/2 phosphorylation was clearly blocked (Fig.1 B). 
However, increasing the concentration of PD184352 to 
20 µM, which blocks MEK1/2 and MEK5 activation (Bain 
et al., 2007), reduced BAFF-induced B cell survival similar to 
U0126 (Fig. 1 C). These observations raised the possibility 
that activation of ERK5 might be critical for BAFF-induced 
mature B cell survival, rather than ERK1/2 activation. Con-
sistent with this hypothesis, we found that two MEK5 inhibi-
tors, BIX02188 and BIX02189 (Tatake et al., 2008), did not 
inhibit MEK1/2 activity (unpublished data) but reduced BAFF-
induced FM B cell survival (Fig. 1 D). BIX02188 and BIX02189 
MEK5 inhibitors also reduced BAFF-induced survival of highly 
purified FACS-sorted FM B cells (Fig. 1 E), ruling out any 
indirect effects of contaminating non-FM B cells. In contrast, 
neither MEK5 inhibitor affected BCR-induced B cell survival 
(Fig. 1, D and E). These results indicated a critical role for ac-
tivation of the ERK5 MAP kinase pathway in BAFF-induced 
mature B cell survival, while BCR survival signaling was inde-
pendent of ERK5 activation.
B cell–specific ERK5 deletion reduces B2 B cell numbers
It was important to confirm the role for ERK5 signaling in 
B cell survival genetically, as pharmacological inhibitors can 
have off-target effects. Since an Erk5-null mutation results in 
embryonic lethality (Nithianandarajah-Jones et al., 2012), we 
crossed mice harboring a conditional Erk5 allele (erk5fl/fl; 
Wang et al., 2006) to mb1-cre+ mice that express Cre at the 
pro–B cell stage in the BM (Hobeika et al., 2006) to generate 
mice with ERK5-deficient B cells. Efficient depletion of ERK5 
protein in splenic mature B cells from mb1-cre+ erk5fl/fl mice 
was confirmed by immunoblotting (Fig. 2 A).
B cell development in the BM was similar between mb1-cre+ 
erk5fl/fl and mb1-cre+ erk5wt/wt mice, with similar absolute num-
bers of pro–B cells, pre–B cells, and immature B cells (Fig. 2 B 
and Fig. S2). Total numbers of B cells in spleen were also 
equivalent in ERK5-deficient and control mice (Fig. 2 C), as 
were the number of splenic transitional type 2 (T2) B cells. 
Numbers of splenic T1 and marginal zone (MZ) B cells were 
both fractionally, but significantly, increased by ERK5 ab-
sence. In contrast, there was approximately a 40% reduction in 
the number of FM B cells in the spleen in ERK5-deficient 
mice compared to controls. The numbers of mature B2 cells 
in the BM (Fig. 2 B) and in peripheral LN (Fig. 2 D), as well 
as the proportion of B2 cells in the peritoneal cavity (Fig. 2 E), 
were also decreased by ERK5 deficiency. In contrast, the fraction 
of peritoneal B1 cells, the survival of which is not regulated by 
BAFF (Mackay et al., 2010), was unaffected by ERK5 absence 
(unpublished data). These results indicated that ERK5 was re-
quired for optimal development and/or homeostasis of mature 
therefore appears to be required for the survival and/or devel-
opment of mature B cells, while activation of the alternative 
NF-B pathway does not appear to be essential.
Phosphatidylinositol (PtdIns) 3-kinase (PI3K) is also acti-
vated by BAFF stimulation of mature B cells (Patke et al., 
2006) as a result of BAFF-induced phosphorylation of the 
CD19 co-receptor (Jellusova et al., 2013). Phosphatidylinositide-
3,4,5-trisphosphate (PIP3) generated then activates down-
stream signaling pathways by recruiting effector molecules to 
the plasma membrane via their PH domains. These include 
Akt, which has critical roles in cell growth and survival 
(Baracho et al., 2011). Pharmacological experiments indicate 
that PI3K activation is required for BAFF-induced survival of 
B cells in vitro (Henley et al., 2008), and additionally regulates 
cellular metabolism and growth by activating the mammalian 
target of rapamycin (mTOR; Patke et al., 2006). Deficiency 
of PTEN, which encodes a phosphatase that converts PIP3 to 
phosphatidlyinositide-4,5-bisphosphate and counteracts the 
activity of PI3 kinases, partially rescues the B cell maturation 
defect of Baff/ mice, strongly supporting a key role for 
PI3K in BAFF-induced B cell survival in vivo (Jellusova et al., 
2013). PI3K signaling stimulates B cell survival by up-regulating 
expression of the pro-survival Bcl-2 family member Mcl-1, 
which is essential for BAFF-induced B cell survival (Woodland 
et al., 2008).
ERK1 and ERK2 MAP kinases are critical for pre-BCR 
induced early B cell development (Yasuda et al., 2008). It 
has been proposed that ERK1/2 activation is required for 
optimal BAFF-induced mature B cell survival (Craxton et al., 
2005). However, this conclusion was based on experiments 
with inhibitors of the ERK1/2 kinases MEK 1 and 2 that are 
now known to be unspecific. In the present study, we show 
that BAFF-induced B cell survival was actually independent 
of ERK1/2 activation but required ERK5 activation. Con-
sistent with this, B cell–specific deletion of ERK5 led to 
a pronounced reduction in mature B2 cell numbers, which 
correlated with impaired survival of ERK5-deficient B cells 
after BAFF stimulation. These data identify the ERK5 MAP 
kinase pathway as a key component in BAFF survival signal-
ing and B cell homeostasis.
RESULTS AND DISCUSSION
BAFF-induced FM B cell survival  
is dependent on MEK5 activity
Evidence linking the prosurvival effects of BAFF-R stimu-
lation to the activation of ERK1/2 MAP kinases in B cells 
(Craxton et al., 2005) is based on the use of the pharmaco-
logical inhibitor U0126, which blocks the catalytic activity 
of the upstream MAP kinase kinases (MAP2K) MEK1 and 
MEK2 (Bain et al., 2007). However, U0126 also inhibits with 
similar potency MEK5, a MAP 2-kinase closely related to 
MEK1 that phosphorylates and activates ERK5 MAP kinase 
(Nithianandarajah-Jones et al., 2012). It was therefore possible 
that the inhibitory effect of U0126 on B cell survival was due 
to blockade of ERK5 activation, rather than ERK1/2.
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WT (Ly5.1+) mice at the ratio 80:20 (Ly5.1/Ly5.2). The 
numbers of B2 cells in LN was reduced by ERK5 deficiency 
in mice reconstituted with BM from only mb1-cre+ erk5fl/fl 
compared to BM from mb1-cre+ erk5wt/wt mice (Fig. 2 F), similar 
to intact donor mice. Competition with WT Ly5.1+ B cells 
resulted in a larger reduction in the numbers of ERK5-
deficient Ly5.2+ B2 cells in LN compared to WT Ly5.2+ B2 
cells. In the spleen, WT Ly5.1+ B cells similarly decreased the 
fraction of ERK5-deficient Ly5.2+ FM B cell numbers com-
pared to WT Ly5.2+ FM B cells, while the fraction of ERK5-
deficient Ly5.2+ MZ B cells was normalized. These data showed 
B2 B cells, consistent with a role for ERK5 in BAFF-induced 
B2 cell survival. However, ERK5 was not needed for the genera-
tion of T2 B cells, in contrast to BAFF and BAFF-R (Mackay 
et al., 2010), indicating that ERK5 signaling was dispensable 
for the BAFF-induced development of transitional B cells.
Mixed BM chimeras were generated to determine whether 
the effect of ERK5 deficiency on the generation of mature 
B2 cells was due to a cell-intrinsic defect or could be res-
cued by WT B cells. The hematopoietic system of irradiated 
Rag1/ mice was reconstituted with mb1-cre+ erk5fl/fl or mb1-cre+ 
erk5wt/wt BM cells (Ly5.2+) alone, or mixed with BM from 
Figure 1. BAFF-induced FM B cell  
survival depends on MEK5 activity.  
(A and B) WT purified splenic FM B cells were 
cultured for 48 h with BAFF or control me-
dium (–) plus 2 µM PD184352 (PD) or vehicle 
control (DMSO). (A) The fraction of live FM  
B cells was determined by flow cytometric analy-
sis of 7AAD staining (mean ± SEM; pooled 
cells cultured in triplicates). Gating strategies 
used are shown in Fig. S1. (B) Lysates of puri-
fied splenic FM B cells were immunoblotted 
for the indicated proteins. (C and D) WT puri-
fied splenic FM B cells were cultured for 48 h 
with BAFF, -IgM, or control medium (-), in 
the presence of 20 µM PD184352, 10 µM 
U0126, 10 µM BIX02188, 10 µM BIX02189, or 
control DMSO. The fraction of live FM B cells 
was determined by flow cytometric analysis 
of 7AAD staining (mean ± SEM; pooled cells 
cultured in triplicates). (E) Sorted splenic FM  
B cells (B220+AA4.1IgM+CD23+) were cultured 
for 48 h with BAFF, -IgM, or control medium 
(-) plus 5 µM BIX02188, 5 µM BIX02189, or 
control DMSO. The fraction of live cells was 
determined as in D. All results are representa-
tive of at least three independent experiments. 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
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deficiency impaired B cell antibody responses. ERK5 defi-
ciency did not affect the production of serum anti-NP IgM 
and IgG1 following immunization with the T-dependent (TD) 
antigen NP27-CGG precipitated in alum (Fig. 3 A). The gen-
eration of anti-NP IgG1+–specific germinal center B cells 
was also equivalent in the presence and absence of ERK5 ex-
pression in B cells. Antibody responses of mb1-cre+ erk5fl/fl and 
mb1-cre+ erk5wt/wt mice to a type-1 T-independent (TI) antigen 
(TNP-LPS) and a type-2 TI antigen (TNP-Ficoll) were also 
tested. The amounts of TNP-specific IgM, IgG2b, IgG2c, and 
IgG3 antibodies detected in sera after TNP-LPS injection 
were the same in both genotypes (Fig. 3 B and not depicted). 
Similarly, the amounts of anti-TNP IgM, IgG1, IgG2b, IgG2c, 
and IgG3 antibodies detected in sera after TNP-Ficoll immu-
nization were unaffected by ERK5 deficiency (Fig. 3 C and 
that the reduction in B2 B cell numbers observed in mb1-cre+ 
erk5fl/fl mice was the consequence of a cell-intrinsic defect, 
and suggested that ERK5-deficient Ly5.2+ B2 cells could not 
compete with WT Ly5.1+ B2 cells for a limiting environmen-
tal resource. In contrast, the increase in MZ B cell numbers in 
intact mb1-cre+ erk5fl/fl mice was not caused by a cell-intrinsic 
ERK5 signaling defect. It is possible that the reduction in FM 
B cell numbers in such mice promotes the differentiation of 
T2 B cells to MZ B cells due to an increase in the local avail-
ability of BAFF.
ERK5 signaling in B cells is dispensable  
for antibody responses
After establishing that ERK5 expression was required to 
maintain normal B2 B cell numbers, we tested whether ERK5 
Figure 2. B cell–specific deletion of ERK5 reduces B2 cell numbers. (A) Purified splenic FM B cells from mb1-cre+ erk5fl/fl mice and mb1-cre+ 
erk5wt/wt control mice were analyzed for ERK5 expression by immunoblotting. (B–F) Flow cytometric analysis of B cell populations in mb1-cre+ erk5wt/wt 
and mb1-cre+ erk5fl/fl mice from the indicated organs, as shown in Fig. S2. (B) Absolute numbers of total B cells (CD19+B220+), pro–B (B220+CD19+IgDIgMCD2), 
pre-B (B220+CD19+IgDIgMCD2+), immature B (B220+CD19+IgDIgM+CD2+), and mature B (B220+CD19+IgD+IgM+CD2+) cells in the BM (mean ± SEM;  
n = 7 mice/genotype) were quantified. (C) Absolute splenic numbers (mean ± SEM; n = 14 mice/genotype) of total B cells (IgM+ or IgD+), immature  
B cells (B220+AA4.1+), separated into transitional T1 B cells (IgMhiCD23) and T2 B cells (IgMhiCD23+) were quantified. Splenic mature B cells (B220+AA4.1), 
separated into FM B cells (IgM+CD23+) and MZ B cells (IgMhiCD23). (D) Absolute numbers (mean ± SEM; n = 14 mice/genotype) of B cells (IgM+CD19+)  
in peripheral LN (pools of single cervical, axillary, and inguinal nodes; mean ± SEM; n = 14 mice/genotype) were quantified. (E) Proportion of B2 
(B220+CD19+CD5CD23+) cells in the peritoneal cavity (mean ± SEM; n = 5 mice/genotype) was quantified. (F) mb1-cre+ erk5wt/wt or mb1-cre+ erk5fl/fl 
Ly5.2+ BM cells were mixed with WT Ly5.1+ BM cells at the indicated ratios, and transferred into sublethally irradiated Rag1/ mice. After 8-wk reconsti-
tution, absolute numbers of Ly5.2+ B2 B cells from LN and spleen were assessed by flow cytometry. Graphs show B2 B cell absolute cell numbers (mean ± 
SEM; n = 8 independent mice/genotype). Numbers below the graphs represents the ratio between WT Ly5.2+ controls compared to ERK5-deficient B cells. 
In A–F, results are representative of at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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signaling pathway and that this was required for optimal mature 
B cell survival in vitro. Consistent with this hypothesis, over-
night BAFF stimulation of FM B cells induced a phosphoryla-
tion shift of ERK5 on SDS-PAGE (Fig. 4 C) that was blocked 
by inhibition of MEK5 but not MEK1/2 kinase activity (Fig. 4, 
D and E). In contrast, BCR stimulation did not promote a 
detectable ERK5 phosphorylation shift (Fig. 4 F) and anti-
IgM–induced FM B cell survival was independent of ERK5 
expression (Fig. 4 A). BAFF-induced phosphorylation of ERK5 
was inhibited with an antibody to BAFF-R (Fig. 4 G). This 
indicated that BAFF stimulated ERK5 phosphorylation via 
BAFF-R and not TACI (transmembrane activator CAML in-
teractor), a BAFF receptor that negatively regulates B cell sur-
vival and is also expressed on FM B cells (Mackay et al., 2010).
It has been proposed that BAFF induces B cell survival 
via ERK1/2 induced phosphorylation and subsequent deg-
radation of the proapoptotic protein Bim (Craxton et al., 
not depicted). ERK5 therefore was not required for B cell 
antibody responses to TD or TI antigens. This suggested that 
BCR-induced clonal expansion in response to TD antigens 
compensated for the fractional reduction in steady-state B2 
cell numbers caused by ERK5 absence. Consistent with this 
hypothesis, ERK5 was not required for BCR-induced FM 
B cell growth or proliferation in vitro (unpublished data).
ERK5 is required for BAFF-induced B cell survival
We next investigated the effect of ERK5 deficiency on B cell 
survival in vitro, focusing on FM B2 B cells whose numbers 
were regulated by cell-intrinsic ERK5 signaling. BAFF-induced 
survival of ERK5-deficient FM B cells was substantially 
reduced compared to WT controls (Fig. 4 A), which did not 
result from decreased BAFF-R expression (Fig. 4 B). Together 
with MEK5 inhibitor experiments, these results suggested 
that BAFF stimulation of BAFF-R activated the MEK5–ERK5 
Figure 3. ERK5 is dispensable for B cell antibody responses to TD and TI antigens. (A) mb1-cre+ erk5fl/fl mice and mb1-cre+ erk5wt/wt control mice 
were immunized with NP27-CGG alum or PBS alum controls. -NP IgM (left) and -NP IgG1 (middle) serum antibody levels were quantified by ELISA 
(mean ± SEM; a.u., arbitrary units), 14 days after NP27-CGG immunization. The right panel represents splenic NP IgG1+ GC B cells 14d after NP27-CGG 
immunization (mean absolute number ± SEM). (B and C) mb1-cre+ erk5fl/fl mice and mb1-cre+ erk5wt/wt control mice were immunized with TNP-LPS (B) or 
TNP-Ficoll (C) and bled at the indicated time points. (B) -TNP IgM (left), -TNP IgG3 (middle) and -TNP IgG2b (right) serum antibody levels were quan-
tified by ELISA (mean ± SEM; a.u., arbitrary units). (C) -TNP IgM (left), -TNP IgG1 (middle), and -TNP IgG2b (right) serum antibody levels were quanti-
fied by ELISA (mean ± SEM; a.u., arbitrary units). All results are representative of two independent experiments (at least four independent mice per 
genotype each).
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pathway. BAFF activation of the alternative NF-B2 pathway 
(Fig. 5 A), assaying levels of NF-B2 p52, and the canonical 
NF-B1 pathway (Fig. 5 B), assaying IKK2 phosphorylation 
of NF-B1 p105 (Lang et al., 2003), were also unaffected by 
ERK5 deficiency.
Mcl1 mRNA expression in ex vivo FM B cells was de-
creased by approximately 50% by the absence of ERK5 
(Fig. 5 C). Furthermore, BAFF induction of Mcl1 mRNA 
in cultured FM B cells was substantially reduced by ERK5 
absence (Fig. 5 D). ERK5 deficiency also reduced ex vivo 
expression of Bcl2a1 mRNA (encoding the pro-survival Bcl2 
family protein A1) and BAFF-induced Bcl2a1 mRNA (Fig. 5, 
C and D) and A1 protein expression (Fig. 5 A). mRNA concen-
trations of Bcl2 and Bcl-xl ex vivo and after BAFF stimulation 
were not unaffected by ERK5 deficiency (unpublished data). 
These data suggested that ERK5 was required for optimal 
2005). However, BAFF stimulation did not alter the abun-
dance of Bim in either mb1-cre+ erk5wt/wt or mb1-cre+ erk5fl/fl 
FM B cells (Fig. 5 A), suggesting that ERK5 did not promote 
B cell survival by regulating Bim levels. BAFF stimulation of 
B cells also induces expression of Mcl1, an antiapoptotic 
member of the Bcl2 protein family that is critical for BAFF-
induced B cell survival (Woodland et al., 2008). BAFF up-
regulation of Mcl1 protein levels in FM B cells was reduced 
by ERK5 deficiency (Fig. 5 A). BAFF controls Mcl1 protein 
levels in part by the Akt-dependent inactivation of Gsk-3, 
which constitutively phosphorylates and induces the proteolysis 
of Mcl1 in unstimulated cells (Maurer et al., 2006). However, 
BAFF induced phosphorylation of Akt (Fig. 5 A) to a simi-
lar degree in mb1-cre+ erk5fl/fl and mb1-cre+ erk5wt/wt FM B cells. 
ERK5 therefore regulated Mcl1 expression levels separately 
from BAFF-induced activation of the PI3K-Akt signaling 
Figure 4. BAFF-induced FM B cell survival 
requires ERK5. (A) Purified splenic FM B cells 
from mb1-cre+ erk5fl/fl mice and mb1-cre+ erk5wt/wt 
control mice were cultured for 48 h with BAFF, 
-IgM, BAFF plus -IgM, or control medium (-). 
The fraction of live FM B cells was determined by 
flow cytometric analysis of 7AAD staining (mean ±  
SEM; n = 3 mice/genotype; triplicate cultures). 
Results are representative of at least three sepa-
rate experiments. (B) BAFF-R protein levels on 
gated AA4.1-B220+IgM+CD23+ FM B cells of the 
indicated genotypes were analyzed directly  
ex vivo by flow cytometry. T cells from mb1-cre+ 
erk5wt/wt mice were used as a negative control. 
(C) Purified splenic FM B cells were cultured for 
16 h ± BAFF. Immunoprecipitated ERK5 from 
whole-cell lysates was incubated ±  phos-
phatase and analyzed by immunoblotting.  
(D and E) Pooled WT purified splenic FM B cells 
were cultured for 16 h with BAFF or control me-
dium (-) plus vehicle control (DMSO), 10 µM 
BIX02188, 10 µM BIX02189, or 2 µM PD184352 
(PD). Cell lysates were immunoblotted. (F) Total 
lysates of purified splenic FM B cells stimulated 
with -IgM were immunoblotted. (G) Pooled WT 
purified splenic FM B cells were cultured for 16 h 
with BAFF or control medium (-) plus BAFF-R 
blocking antibody or isotype control. Total cell 
lysates were immunoblotted. All results are repre-
sentative of two or more independent experi-
ments. ****, P < 0.0001.
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Figure 5. Optimal BAFF induction of Mcl1 and A1 expression requires ERK5. (A and B) Purified splenic FM B cells from mb1-cre+ erk5fl/fl mice and 
mb1-cre+ erk5wt/wt control mice were cultured with BAFF or control medium (-) for 16 h (A) or 1 h (B). Whole-cell lysates were immunoblotted for the 
indicated proteins. Results are representative of three independent experiments (3 mice/genotype each). In A, graphs represent mean band intensities for 
the indicated proteins (±SEM; n ≥ 5/genotype each), normalized to tubulin loading control. In B, quantitation of band intensities (6 mice/genotype) dem-
onstrated that ERK5 deficiency did not significantly alter P-p105 levels in BAFF-stimulated cells (data not shown). (C) mRNA levels of the indicated genes 
from rested purified splenic FM B cells from mb1-cre+ erk5fl/fl mice and mb1-cre+ erk5wt/wt control mice were determined by quantitative RT-PCR. Data 
were normalized to Hprt1 mRNA and are represented as mean fold change (±SEM) relative to unstimulated WT cells. (D) Purified splenic FM B cells from 
the indicated mouse strains were cultured in duplicate with BAFF for 16 h and mRNA expression was assessed as indicated in C. (E) Purified splenic 
890 ERK5 regulation of B cell survival | Jacque et al.
rapidly in the absence of ERK5 expression, consistent with a 
key role for ERK5 signaling in maintaining their survival.
Our study has established a critical role for the MEK5–
ERK5 signaling in BAFF-induced mature B cell survival, pro-
viding an explanation for the reduction in B2 cell numbers in 
mice lacking ERK5 expression in their B cell lineage. Recent 
data have indicated that the alternative NF-B2 signaling path-
way may be dispensable for BAFF-induced mature B cell sur-
vival (Jellusova et al., 2013). In contrast, pharmacological and 
genetic experiments demonstrate an important role for BAFF 
activation of PI3K to promote the survival of peripheral B cells 
(Patke et al., 2006; Jellusova et al., 2013). BAFF stimulation of 
Akt phosphorylation was independent of ERK5 activation, 
suggesting that ERK5 and PI3K signaling independently regu-
late BAFF-induced mature B cell survival. However, the out-
puts of these signaling pathways converge on Mcl1, which is 
required for BAFF-induced B cell survival (Woodland et al., 
2008; Jellusova et al., 2013). ERK5 signaling induces Mcl1 
transcription, whereas PI3K–Akt signaling stabilizes Mcl1 pro-
tein via inhibition of GSK-3. In line with this, experiments 
with PI3K inhibitors revealed that PI3K–Akt and ERK5 sig-
naling cooperate to promote BAFF-induced B cell survival.
In addition to BAFF stimulation, the survival of periph-
eral B cells depends on a tonic signal from the BCR that is 
distinct from that induced by antigen binding (Mackay et al., 
2010). Activation of PI3K or inactivation of its inhibitor 
PTEN rescues the survival of BCR-deficient B cells, suggesting 
that the BCR promotes mature B cell survival via activation 
of PI3K (Srinivasan et al., 2009). BCR expression is needed to 
maintain peripheral B cells due to the BAFF-R requiring Syk 
tyrosine kinase, a key signal transducer from the BCR, to acti-
vate PI3K and promote B cell survival (Schweighoffer et al., 
2013). However, BCR-deficient PI3K-rescued B cells are still 
dependent on BAFF for survival in vitro (Srinivasan et al., 2009). 
Our data raise the possibility that BAFF stimulation of such 
cells is needed to activate the ERK5 MAP kinase pathway, 
which is not required for BCR-induced survival signaling.
MATERIAL AND METHODS
Mouse strains. Mouse strains were bred in the specific pathogen–free ani-
mal facility of the National Institute for Medical Research (NIMR). 7-12-
wk–old mice were used for all experiments, which were performed in 
accordance with the UK Home Office regulations and approved by the 
NIMR Ethical Review Panel. Rag1/ (Mombaerts et al., 1992), erk5fl/fl 
(Wang et al., 2006), and mb1-cre+ (Hobeika et al., 2006) mouse strains were 
all fully backcrossed onto a C57BL/6 background.
transcriptional up-regulation of Mcl1 and Bcl2a1 after BAFF 
stimulation, providing a possible explanation for the reduced 
survival of ERK5-deficient B cells compared to WT.
Activation of the PI3K–Akt pathway is required for 
BAFF-R survival signaling (Rickert et al., 2011). Because 
BAFF-R induced Akt phosphorylation independently of 
ERK5 expression, we tested the effect of blocking PI3K-Akt 
and ERK5 signaling pathways simultaneously on BAFF- 
induced FM B cell survival in vitro. Pretreatment of cells with 
the small molecule PI3K inhibitors PI-103 (Bain et al., 2007) 
or GDC-0941 (Folkes et al., 2008) reduced the survival of 
FM B cells after BAFF stimulation to a similar degree to that 
caused by genetic deletion of ERK5 (Fig. 5 E; 40% live 
cells). However, treatment of ERK5-deficient mb1-cre+ erk5fl/fl 
FM B cells with either PI-103 or GDC-0941 reduced the 
fraction of live cells to <10% in BAFF-containing cultures. The 
PI3K-Akt and ERK5 signaling pathways therefore function 
cooperatively to promote the survival of FM B cells.
Antibody blockade of BAFF leads to the rapid loss of 
mature B cells in vivo, indicating that BAFF stimulation is 
continuously required to promote mature B cell survival 
(Mackay et al., 2010). To investigate whether tonic BAFF 
stimulation activates the ERK5 signaling pathway in mature 
B cells, WT C57BL/6 mice were injected intraperitoneally 
twice (day 1 and 3) with neutralizing BAFF antibody or iso-
type control antibody, and culled at d 4. Purified FM B cells 
were immediately lysed, and extracted proteins were immuno-
blotted for ERK5. In mice injected with control antibody, a 
slower mobility phosphorylated form of ERK5 was clearly 
evident, but this was lost after anti-BAFF injection (Fig. 5 F). 
These results suggested that tonic BAFF stimulation of FM 
B cells continuously induced ERK5 phosphorylation and might 
be required to maintain FM B cell survival in vivo.
To determine whether ERK5 regulated FM B cell turn-
over, mb1-cre+ erk5fl/fl and mb1-cre+ erk5wt/wt mice were injected 
daily with BrdU for 5 d. Spleens were harvested at day 6 and 
BrdU labeling in splenic B cell subsets was determined by flow 
cytometry (Fig. 5 G). ERK5 deficiency had no effect on BrdU 
labeling of T1 or MZ B cells, whereas there was a small increase 
in the fraction of BrdU+ T2 cells. In contrast, the fraction of 
BrdU+ FM B cells was increased 2.5-fold in the absence of 
ERK5. 7-AAD labeling demonstrated that ERK5 deficiency 
did not alter the proportion of S-phase cells at any stage of 
B cell development in the BM or spleen (unpublished data). 
These results suggested that FM B cells turned over more 
FM B cells from the indicated mouse strains were cultured for 48 h with BAFF or control medium (-) plus PI-103 (PI; 0.5 µM), GDC-0941 (GDC; 0.5 µM),  
or vehicle control (DMSO). The fraction of live FM B cells was determined by flow cytometric analysis of 7AAD staining (mean ± SEM; triplicates). In C–E, 
results are representative of three separate experiments (three mice/genotype each). (F) WT mice were injected intraperitoneally twice (day 1 and 3)  
with 100 µg anti-BAFF antibody or isotype control. At day 4, splenic FM B cells were purified and cell lysates immunoblotted. Results are representative of 
two independent experiments (4 mice/genotype each). Graphs (right) represent mean band intensity (±SEM; n = 7/genotype each), normalized to tubulin 
loading control. (G) mb1-cre+ erk5fl/fl mice and mb1-cre+ erk5wt/wt control mice were injected intraperitoneally with BrdU daily for 5 days. Spleens were 
harvested at day 6 and BrdU+ cells assayed by flow cytometry. Results are representative of two independent experiments (five mice/genotype each). 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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FACSARIA II cell sorters, to achieve >99% purity. Cells were cultured at a 
density of 2–5 × 106/mL in complete medium (DMEM plus 10% heat inac-
tivated FCS [Lonza], 100 U/ml Penicillin, 100 µg/ml Streptomycin, 100 µM 
nonessential amino acids, 100 mM Na-Pyruvate, and 50 µM 2-mercaptoethanol), 
and stimulated with anti-IgM (10 µg/ml; Jackson ImmunoResearch Labora-
tories), or BAFF (200 ng/ml; PeproTech).
For in vitro survival assays, 3 × 105 B cells were cultured in a 96-well 
tissue-culture plate in complete medium (200 µl) ± stimulation (see above). 
Cells were harvested 2 d later, stained for a B cell marker (B220 or CD19) 
and 7-amino-actinomycin D (7-AAD; Sigma-Aldrich). Cells were preincu-
bated with pharmacological inhibitors or DMSO vehicle control for 30 min 
before stimulation. MEK inhibitors (PD184352, U0126, BIX02188, and 
BIX02189) were purchased from Selleckchem, PI-103 PI3K inhibitor from 
BioVision, and GDC-0941 PI3K inhibitor from SYNkinase. Mouse BAFF-R 
blocking antibody (R&D Systems; 5 µg/ml) or isotype control (R&D Systems) 
were added to cultures simultaneously with BAFF. Cells were harvested and 
lysed 16 h later.
Protein analyses. For immunoblots of total lysates, FM B cells (1 × 107 cells 
per point) were lysed in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 
2 mM EDTA, 50 mM NaF, 2 mM Na4P2O7, 5 mM dithiothreitol, 1 mM 
Na3VO4, protease inhibitors [Roche], 0.5% deoxycholate, 1% Triton X-100, 
and 0.1% SDS). After centrifugation, lysates (10–15 µg) were mixed with an 
equal volume of 2× SDS-PAGE sample buffer. For in vitro dephosphoryla-
tion of ERK5, cells were lysed in S-buffer (10 mM Tris, pH 7.5, 150 mM 
NaCl, 5 mM EDTA, 1% Triton X-100, and protease inhibitors [Roche] with 
or without phosphatase inhibitors [10 mM Na3VO4 and 50 mM NaF]). After 
overnight immunoprecipitation, beads were washed and incubated with 400 U 
Lambda phosphatase (New England Biolabs) following the manufacturer’s 
instruction (30°C for 30 min). Reactions were stopped by addition of Laem-
mli sample buffer and heating to 100°C. Isolated proteins were then resolved 
by SDS-PAGE and immunoblotted. Band intensities were quantified using 
a GS-800 Calibrated Densitometer (Bio-Rad Laboratories).
ERK5, ERK1/2, P-ERK1/2, P-Akt (Ser473), Akt, Foxo1, P-NF-B1 
p105, and Bim antibodies were purchased from Cell Signaling Technology, 
while Mcl1 antibody was from Rockland Immunochemistry. NF-B1 anti-
body was purchased from Delta Biolabs and NF-B2 antibody has been 
previously described (Coope et al., 2002). A1 antibody was provided by 
M. Herald (Walter and Eliza Hall Institute of Medical Research [WEHI], 
Melbourne, Australia) and tubulin mAb by K. Gull (University of Oxford, 
Oxford, England, UK).
Real-time quantitative PCR. RNA from stimulated and unstimulated 
FM B cells (5 × 106/ml) was isolated using the RNeasy kit. Contaminating 
DNA was removed using RNase-free DNase set (QIAGEN) according to 
manufacturer’s instructions and by DNase treatment (Roche). cDNA was 
produced using the SuperScript III First-Strand Synthesis SuperMix for 
qRT-PCR (Life Technologies) and standard protocols. Expression of target 
genes were determined by real-time PCR using a Perkin Elmer ABI Prism 
7000 Sequence Detection System, and commercial FAM labeled probes 
(Applied Biosystems) with the TaqMan Gene Expression Master Mix (Ap-
plied Biosystems). Target gene mRNA levels were normalized against Hprt 
mRNA levels.
Statistical analysis. All data analyses were performed using GraphPad soft-
ware (GraphPad Software Inc.). In vitro data were compared using Student’s 
t-test (two tailed and unpaired test). For in vivo experiments, all statistical 
comparisons were carried out using the nonparametric two-tailed Mann-
Whitney test. Statistically significant differences are indicated on the figures. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Online supplemental material. Fig. S1 shows the flow cytometry gating 
strategy for Fig. 1, and Fig. S2 shows the flow cytometry gating strategy 
for Fig. 2. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20142127/DC1.
BM chimeras. BM cells were harvested from femora and tibiae of the indi-
cated donor mice, and resuspended in ACK lysis buffer (155 mM NH4Cl, 
10 mM KHCO3, and 100 µM EDTA) to lyse red blood cells. Cells (4-5 × 106 
per mouse) were then transferred by intravenous injection into sublethally 
irradiated Rag1/ mice (500 rad; Cs source). For competition experiments, 
BM cell suspensions from CD45.1+ C57BL/6 were mixed with either 
mb1-cre+erk5fl/fl or mb1-cre+erk5wt/wt CD45.2+ BM cells at a 80:20 ratio. Chi-
meric mice were analyzed 8 wk after reconstitution.
Antibody responses. For TD antibody responses, experiments were per-
formed as previously described (Jacque et al., 2014). For TI antibody responses, 
mice were immunized intraperitoneally with 50 µg of either TNP-LPS (T1) or 
TNP-Ficoll (T2) in PBS (Biosearch Technologies). Mice were bled before 
immunization and at day 7, 14, and 21 after immunization. The production 
of TNP-specific immunoglobulins was monitored by ELISA, using 96-well 
Maxisorp ELISA plates pretreated with 50 µl/well of 33 µg/ml TNP4-BSA 
(Biosearch Technologies). Antibody isotypes and subclasses were detected by 
ELISA (SouthernBiotech).
In vivo BAFF blockade. Mice were injected intraperitoneally twice (day 1 
and 3) with 100 µg anti-BAFF antibody (10F4; GlaxoSmithKline) or isotype 
control. At day 4, mice were culled and splenic FM B cells were purified.
BrdU labeling. BrdU (Sigma-Aldrich, 1 mg in 200 µl PBS) was injected 
intraperitoneally daily for 5 d. At day 6, mice were culled and spleens were 
harvested. BrdU+ cells were assayed by flow cytometry using the FastImmune 
anti–BrdU-FITC antibody (BD).
Flow cytometry. Single-cell suspensions were generated from peripheral 
LN (pools of single cervical, axillary, and inguinal nodes), spleen, BM, and 
peritoneal washes by gentle homogenization through nylon mesh filters 
(70 µM; BD). Erythrocytes in BM and spleens were lysed with ACK lysis 
buffer before staining, and cell concentrations determined using a Casy Counter 
(Scharfe Instrument Systems). CD1d-PE and CD1d-bio (clone 1B1), CD21-
FITC (eBio8D9), CD23-PE (B3B4), B220-FITC, B220-PE, B220-APC and 
B220-eFluor450 (RA3-6B2), CD93-APC (AA4.1), IgM-PECy7 (II/41), 
IgD-FITC, IgD-eFluor450, IgD-PE and IgD-bio (11-26), Ly5.1-FITC and 
Ly5.1-APC (A20), Ly5.2-FITC and Ly5.2-APC-eFluor780 (104), CD43-
bio (eBioR2/60), IgG1-APC (X56), Gr1-bio (RB6-8C5), CD11b-Bio 
(M1/70), CD11c-Bio (N418), CD5-PE (53-7.3), CD19-FITC (MB19-1), 
TCR-FITC (H57-597), and BAFF-R-FITC (eBio7H22-E16) were ob-
tained from eBioscience. CD4-PerCP (RM4-5), B220-PcP (RA3-6B2), 
B220-BV605 (RA3-6B2), CD19-BV786 (6D5), and CD8-PerCP (53-6.7) 
were purchased from BioLegend; CD2-PE (RM2-5), CD9-bio (KMC8), 
CD21-PE (7G6), Streptavidin-PerCP (554064), and GL7-FITC (Ly77) from 
BD; PNA-Bio (FL-1075) from Vector Laboratories; CD19-APC (RM705) 
and CD23-APC (MCD2305) from Life Technologies; and CD93-PE (REA298) 
from Miltenyi Biotec. For thymus-dependent (TD) antibody response assays, 
NP27-BSA (Biosearch Technologies) was labeled with the LYNX rapid RPE 
antibody conjugation kits (AbD Serotec), according to the manufacturer’s 
protocol. Dead cells were labeled with the Live/Dead Fixable Near-IR Dead 
Cell Stain kit (Life Technologies) or Zombie Aqua Fixable Viability kit (Bio-
Legend) before antibody staining.
Stained cells were analyzed by flow cytometry on a CyAn ADP Ana-
lyzer (Beckman Coulter), FACS LSRFORTESSA X20 Analyzer (BD), 
or FACSCANTO II Analyzer (BD). Data analyses were performed with 
FlowJo 887 software (Tree Star).
B cell isolation and in vitro culture. Splenic FM B cells were isolated by 
sequential hypotonic RBC lysis, followed by magnetic bead separation using a 
mixture of biotinylated anti-CD43 and anti-CD1d antibodies and Streptavidin-
coupled Dynabeads (Life Technologies). Purity of the resulting FM B cell 
population (B220+CD23hiCD21lo) was >96–98% as assessed by flow cy-
tometry. Where indicated, FM B cells were fractionated by flow cytometry 
(B220+AA4.1IgM+CD23+), using MoFlo XDP (Beckman Coulter) and 
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